Close Menu

Not This Time

The first human stem-cell based drug failed two late-stage clinical trials, reports the New York Times. The drug, Prochymal, from Osiris Therapeutics was made from mesenchymal stem cells from healthy young adults and was found to be no more effective than placebo in treating graft-versus-host disease. Prochymal did, however, appear to have an effect in a subset of patients. "Prochymal is having a clear effect in the liver, and that is the most underserved patient population," CEO C.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.